REPORT ID 2844

China Renal Cell Cacinoma Drugs Market Research Report 2017

Publish Date
11-Dec-17
Pages
106
Format
Electronic (PDF)

The global Renal Cell Cacinoma Drugs market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

China plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2022, with a CAGR of xx%.

This report studies the Renal Cell Cacinoma Drugs development status and future trend in China, focuses on top players in China, also splits Renal Cell Cacinoma Drugs by type and by applications, to fully and deeply research and reveal the market general situation and future forecast.

The major players in China market include
    Merck & Co., Inc.
    Exelixis Inc
    Argus Therapeutics, Inc.
    Bristol-Myers Squibb
    Genentech
    Immatics Biotechnologies
    AVEO Oncology
    Eisai
    Acceleron
    Rexahn Pharmaceuticals
    Bionomics
    Cerulean Pharma Inc
    Celldex Therapeutics
    TVAX Biomedical
    TRACON Pharmaceuticals

Geographically, this report splits the China market into six regions,
    South China
    East China
    Southwest China
    Northeast China
    North China
    Central China
    Northwest China

On the basis of product, this report displays the sales volume (K Pcs), revenue (Million USD), product price (USD/Pcs), market share and growth rate of each type, primarily split into
    Sutent(Sunitinib)
    Nexavar(Sorafenib)
    Votrient(Pazopanib)
    Avastin(Bevacizumab)
    Afinitor(Everolimus)
    Inlyta(Axitinib)
    Torisel(Temsirolimus)
    Proleukin(Aldesleukin)

On the basis of the end users/application, this report covers
    Mucinous Tubular and Spindle Cell Carcinoma (MTSCC)
    Multilocular Cystic Clear Cell Renal Cell Carcinoma
    Tubulocystic Renal Cell Carcinoma
    Thyroid-Like Follicular Renal Cell Carcinoma
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

China Renal Cell Cacinoma Drugs Market Research Report 2017
1 Renal Cell Cacinoma Drugs Overview
    1.1 Product Overview and Scope of Renal Cell Cacinoma Drugs
    1.2 Classification of Renal Cell Cacinoma Drugs by Product Category
        1.2.1 China Renal Cell Cacinoma Drugs Sales (K Pcs) Comparison by Type (2012-2022)
        1.2.2 China Renal Cell Cacinoma Drugs Sales (K Pcs) Market Share by Type in 2016
        1.2.3 Sutent(Sunitinib)
        1.2.4 Nexavar(Sorafenib)
        1.2.5 Votrient(Pazopanib)
        1.2.6 Avastin(Bevacizumab)
        1.2.7 Afinitor(Everolimus)
        1.2.8 Inlyta(Axitinib)
        1.2.9 Torisel(Temsirolimus)
        1.2.10 Proleukin(Aldesleukin)
    1.3 China Renal Cell Cacinoma Drugs Market by Application/End Users
        1.3.1 China Renal Cell Cacinoma Drugs Sales (K Pcs) and Market Share Comparison by Applications (2012-2022)
        1.3.2 Mucinous Tubular and Spindle Cell Carcinoma (MTSCC)
        1.3.3 Multilocular Cystic Clear Cell Renal Cell Carcinoma
        1.3.4 Tubulocystic Renal Cell Carcinoma
        1.3.5 Thyroid-Like Follicular Renal Cell Carcinoma
        1.3.6 Others
    1.4 China Renal Cell Cacinoma Drugs Market by Region
        1.4.1 China Renal Cell Cacinoma Drugs Market Size (Million USD) Comparison by Region (2012-2022)
        1.4.2 South China Renal Cell Cacinoma Drugs Status and Prospect (2012-2022)
        1.4.3 East China Renal Cell Cacinoma Drugs Status and Prospect (2012-2022)
        1.4.4 Southwest China Renal Cell Cacinoma Drugs Status and Prospect (2012-2022)
        1.4.5 Northeast China Renal Cell Cacinoma Drugs Status and Prospect (2012-2022)
        1.4.6 North China Renal Cell Cacinoma Drugs Status and Prospect (2012-2022)
        1.4.7 Central China Renal Cell Cacinoma Drugs Status and Prospect (2012-2022)
    1.5 China Market Size (Sales and Revenue) of Renal Cell Cacinoma Drugs (2012-2022)
        1.5.1 China Renal Cell Cacinoma Drugs Sales (K Pcs) and Growth Rate (%)(2012-2022)
        1.5.2 China Renal Cell Cacinoma Drugs Revenue (Million USD) and Growth Rate (%)(2012-2022)

2 China Renal Cell Cacinoma Drugs Market Competition by Players/Manufacturers
    2.1 China Renal Cell Cacinoma Drugs Sales and Market Share of Key Players/Manufacturers (2012-2017)
    2.2 China Renal Cell Cacinoma Drugs Revenue and Share by Players/Manufacturers (2012-2017)
    2.3 China Renal Cell Cacinoma Drugs Average Price (USD/Pcs) by Players/Manufacturers (2012-2017)
    2.4 China Renal Cell Cacinoma Drugs Market Competitive Situation and Trends
        2.4.1 China Renal Cell Cacinoma Drugs Market Concentration Rate
        2.4.2 China Renal Cell Cacinoma Drugs Market Share of Top 3 and Top 5 Players/Manufacturers
        2.4.3 Mergers & Acquisitions, Expansion in China Market
    2.5 China Players/Manufacturers Renal Cell Cacinoma Drugs Manufacturing Base Distribution, Sales Area, Product Types

3 China Renal Cell Cacinoma Drugs Sales and Revenue by Region (2012-2017)
    3.1 China Renal Cell Cacinoma Drugs Sales (K Pcs) and Market Share by Region (2012-2017)
    3.2 China Renal Cell Cacinoma Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
    3.3 China Renal Cell Cacinoma Drugs Price (USD/Pcs) by Regions (2012-2017)

4 China "&B1&" Sales and Revenue by Type/ Product Category (2012-2017)"
    4.1 China Renal Cell Cacinoma Drugs Sales (K Pcs) and Market Share by Type/ Product Category (2012-2017)
    4.2 China Renal Cell Cacinoma Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
    4.3 China Renal Cell Cacinoma Drugs Price (USD/Pcs) by Type (2012-2017)
    4.4 China Renal Cell Cacinoma Drugs Sales Growth Rate (%) by Type (2012-2017)

5 China "&B1&" Sales by Application (2012-2017)"
    5.1 China Renal Cell Cacinoma Drugs Sales (K Pcs) and Market Share by Application (2012-2017)
    5.2 China Renal Cell Cacinoma Drugs Sales Growth Rate (%) by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6 China Renal Cell Cacinoma Drugs Players/Suppliers Profiles and Sales Data
    6.1 Merck & Co., Inc.
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Merck & Co., Inc. Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Exelixis Inc
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Exelixis Inc Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Argus Therapeutics, Inc.
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Argus Therapeutics, Inc. Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Bristol-Myers Squibb
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Bristol-Myers Squibb Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Genentech
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Genentech Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Immatics Biotechnologies
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Immatics Biotechnologies Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 AVEO Oncology
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 AVEO Oncology Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Eisai
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Eisai Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Acceleron
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Acceleron Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Rexahn Pharmaceuticals
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Renal Cell Cacinoma Drugs Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Rexahn Pharmaceuticals Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Bionomics
    6.12 Cerulean Pharma Inc
    6.13 Celldex Therapeutics
    6.14 TVAX Biomedical
    6.15 TRACON Pharmaceuticals

7 Renal Cell Cacinoma Drugs Manufacturing Cost Analysis
    7.1 Renal Cell Cacinoma Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Renal Cell Cacinoma Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Renal Cell Cacinoma Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Renal Cell Cacinoma Drugs Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 China Renal Cell Cacinoma Drugs Market Size (Sales and Revenue) Forecast (2017-2022)
    11.1 China Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (Million USD) Forecast (2017-2022)
    11.2 China Renal Cell Cacinoma Drugs Sales (K Pcs) Forecast by Type (2017-2022)
    11.3 China Renal Cell Cacinoma Drugs Sales (K Pcs) Forecast by Application (2017-2022)
    11.4 China Renal Cell Cacinoma Drugs Sales (K Pcs) Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Methodology and Data Source
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer
    13.4 Author List